Lonza to Invest in Mid-Scale Biologics, Cell Therapy Manufacturing
Lonza announces addition of mid-scale biologics manufacturing capacity and cell-therapy suites at Portsmouth, NH site.
Lonza Pharma & Biotech announced plans to add mid-scale mammalian capacity and cell-therapy suites at the company’s Portsmouth, NH facility. The investment was announced in a press statement on May 4, 2018.
The company plans to install multiple 6000-L bioreactors with construction expected to start in late 2018. The hybrid facility will feature full-suite process analytic technology, multi-variate analysis, and single-use technologies in an existing building.
Lonza also announced the installation of multiple cell-therapy suites at the Portsmouth site. In February 2018, the company identified Portsmouth as a clinical and commercial manufacturing center for cell therapies, providing customers access to facilities for Phase I through to commercial manufacturing in one location. The facility is expected to be operational by late 2018.
Source: Lonza Pharma & Biotech
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
